Drugs / BI 1265162
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04267276 | Feb → Apr 2020 | — | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03907280 | Apr → Dec 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03576144 | Jul → Dec 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03349723 | Nov 2017 → Mar 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04059094 | Sep 2019 → Apr 2020 | cystic fibrosis | Boehringer Ingelheim | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1265162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04059094 ↗ |
| Action | Inhibit | “BI 1265162 is an ENaC inhibitor with demonstrated pre-clinical efficacy and safety already demonstrated in humans.” PMID 34385272 ↗ Feb 2022 |
| Route | Inhaled | “following inhalative administration of single rising doses.” NCT03349723 ↗ |